Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial.

ABSTRACT:

Background

Chronic kidney disease (CKD) is a devastating progressive condition accompanied with high morbidity and mortality rates. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently proven their renoprotective effects, whereas evidence for metformin remains limited but suggestive of potential benefit. This study aimed at comparing the efficacy and safety of metformin versus empagliflozin, a SGLT2 inhibitor, on retarding CKD progression with exploring supposed mechanistic pathways in clinical settings.

Methods

In this 12-month randomized controlled trial, 120 moderate CKD patients were randomized into three groups: metformin 1000 mg/day (n = 40) or empagliflozin 10 mg/day (n = 40), both added orally to standard treatment, or control who continued standard of car

SUBMITTER: Mahboub BM 

PROVIDER: S-EPMC12801430 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature